Experimental studies led to testing of deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) as a new therapy to treat freezing of gait (FOG) in Parkinson disease (PD). Despite promising initial results fueling a growing interest toward that approach, several clinical studies reported heterogeneity in patient responses. Variation in the position of electrode contacts within the rostral brainstem likely contributes to such heterogeneity. OBJECTIVE: To provide anatomoclinical correlations of the effect of DBS of the caudal mesencephalic reticular formation (cMRF) including the PPN to treat FOG by comparing the normalized positions of the active contacts among a series of 11 patients at 1-and 2-yr follow-up and to provide an optimal target through an open-label study.
Functionally, the area is also referred to as the mesencephalic locomotor region 5 and is part of the reticular activating system. 8 Deep brain stimulation (DBS) of the PPN was proposed as a new therapy to treat levodopa-resistant gait disorders in Parkinson disease (PD). 9, 10 Several studies stressed the variability of clinical responses 6, 7, [11] [12] [13] possibly related to patient selection, stimulation parameters and/or position of the electrode within the PPN. 14 Based on a new brainstem normalized coordinate system (BNCS) associated with the pontomesencephalic junction (PMJ), the aim of the present study was to evaluate the anatomoclinical correlations between active contacts position and clinical outcomes at 24 mo follow-up, in PD patients implanted in the cMRF for severe gait disorders.
METHODS

Patients
Eleven patients with PD and severe gait disorders were included in a bilateral cMRF implantation protocol. The protocol was approved by the local ethic committee (06-CHUG-21) and all patients provided written informed consent. See Table 1 for patient clinical and demographic characteristics. Of the 11 patients, 7 had undergone a prior subthalamic nucleus (STN)-DBS electrode implantation. The 4 remaining patients received only bilateral cMRF-DBS electrodes.
Inclusion and Exclusion Criteria
Detailed criteria have previously been described. 7 Briefly, patients were included if gait disorders and freezing of gait (FOG) were their main complaint, while other PD signs were satisfactorily controlled by medication and/or STN stimulation.
Clinical Evaluation
Evaluation was assessed using both objective motor measures and questionnaires. The same evaluations were carried out prior to surgery and 1 and 2 yr after, under both OFF and ON medication conditions. Assessments were performed after an overnight fasting and withdrawal of medication, and then after administration of 120% of the usual preoperative morning levodopa dose. STN stimulation was ON during the evaluations. Patient #6 was treated only by STN stimulation and therefore was not tested ON medication. Clinical evaluations included the unified Parkinson Disease Rating Scale (UPDRS) parts II (activities of daily living) and III (motor part), as well as a gait test including FOG provoking circumstances. 7 A composite gait score was computed based on the sum of items 14 (freezing) and 15 (gait) of the UPDRS II and item 30 (gait) of the UPDRS III. Postural stability was examined using a composite score based on the sum of item 13 (falls unrelated to freezing) of UPDRS II and item 29 (postural stability) of UPDRS III. Quality of life was assessed using the PDQ-39, with special attention to the mobility subscore. For quantitative assessment, the gait test was performed while wearing adapted shoes (Stride Analyzer, B&L Engineering, Santa Ana, California) that enabled acquisition of foot-floor contact data.
Finally, patients recorded FOG episodes and falls on a diary that was examined at each visit. Classification of the patients into good and bad responders was based on the results of the objective assessments 2 yr after surgery, the PDQ-39 scores, the patients' diary and the clinical observation made during patients' regular visits. When the sets of observations were not fully congruent, we favored those reflecting the daily condition of the patients.
Imaging Protocol
Preoperative 1.5 T, stereotactic T1 and T2 magnetic resonance images were acquired and fused (Voxim, Chemnitz, Germany). Ventriculographic landmarks were also obtained by direct injection of iopamiron using perioperative X-ray sequences (BioScan, Geneva, Switzerland). Postoperative, T1, and T2 magnetic resonance imaging (MRI) control was performed in all patients.
Targeting
For the first 6 patients, cMRF targeting was performed with the central electrode trajectory parallel to the floor of the fourth ventricle, passing through posterior commissure (PC) plane with a 14
• -20
• lateromedian angle (see Figure 1 ). Target depth was set at -13 mm below PC and 6 mm lateral. Using a Bengun, a second trajectory was defined 2 mm posterior to the central one. An additional third trajectory was occasionally performed 2 mm anterior or lateral to the central trajectory. For the last 5 consecutive patients, we targeted the cMRF on purpose more posteriorly based on accumulated experience. Coordinates were AP = 2 to 3 mm posterior to PC, Lat = 6 mm; depth = level of the PMJ, angle adapted to the brainstem orientation.
Surgery
Surgery was performed under local anesthesia and was similar to that previously used in routine for all DBS cases. [16] [17] [18] A chronic DBS electrode (Model 3389, Medtronic, Dublin, Ireland) was inserted along the trajectory in which the highest thresholds of side effect together with highest cell activities were obtained.
Intraoperative Assessment of Micro and Macro/DBS Electrode Position
Positions of the macro contacts were monitored all along the trajectory using a biorthogonal X-ray system (see Figure 1 ).
The Brainstem Normalized Coordinate System
To overcome brainstem anatomic variability, we defined a new BNCS based on rostral brainstem landmarks centered on the PMJ (see Figure 2 ; Appendix, Supplemental Digital Content 1).
Normalization Procedure
DBS active contact coordinates were first measured from X-Ray ventriculography in the Talairach system then transferred on the 3-D MRI according to the same ventricular landmarks and finally were plotted onto the BNCS. For normalization procedure, see Appendix, Supplemental Digital Content 1. 
Graphical Representation
Three-dimensional graphical representations were created using a software developed in Python with the BrainVisa/Anatomist toolbox. 19 All electrode contacts were displayed as spheres on a PD patient template image. For all patients, only cathode contacts were plotted. For patients who were stimulated using 1 anode and 2 cathodes, the 2 active contacts were included in the analysis.
Immunohistochemistry
Postmortem human brain tissue was obtained from a female deceased from a non-neurodegenerative disease. The choline acetyltransferase (ChAT), immunostaining was done using a standard immunoperoxidase method, as previously described.
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Statistics
Description of active contact coordinates' distribution was performed by calculating the mean, standard deviation and range. Mann-Whitney U-test was used to test the differences of normalized coordinates between the groups of responders. After verifying the normality of distributions, 2 (medication OFF-medication ON) by 3 (presurgery-12 mo of follow-up-24 mo of follow-up) ANOVAs with repeated measures for the 2 factors were performed to examine the effect of cMRF surgery on the composite gait score, composite postural stability score, and PDQmobility subscore.
RESULTS
Surgery Safety
Surgery was uneventful. In patients who were implanted in STN prior to cMRF surgery, no single interference with the previous electrodes was noticed. One patient showed severe retropulsion postoperatively that resolved within a week. Another patient had 2 epileptic seizures 1 wk after surgery. These patients fully recovered from these adverse effects.
No severe adverse event was recorded except in 1 patient (#9) who fell down due to postural instability both OFF and ON stimulation and resulted in a vertebral fracture. Postoperative MRI did not reveal any hematoma. At 2-yr follow-up, no hardware-related complications were reported. During surgery, microstimulation tests on each trajectory, at different depths, did not yield any clinical response regarding either akinesia or rigidity. Clinical Follow-up Detailed clinical evaluation of the cMRF DBS at 24 mo postsurgery is provided in Table 2 . In patients with both STN and cMRF electrodes, STN stimulation parameters were unchanged after cMRF surgery. One patient (#8) was not evaluated at 12-mo follow-up, as he had stopped complying with the experimental protocol after the sixth month. Patient (#9) experienced a severe backward fall the week before the 12-mo follow-up evaluation. As postural instability has continued to worsen ever since, no postoperative evaluation has been carried out and cMRF stimulation was discontinued in this case. Therefore, postoperative evaluations were carried out on 9 patients. Yet, another patient (#3) displayed severe akinesia and was unable to perform the objective gait assessment when OFF medication at the 12-mo follow-up assessment.
As already reported, 7 optimal effects were obtained at low frequency stimulation 10 to 30 Hz (see Table 3 ). In addition, maintenance of beneficial effects of cMRF stimulation required regular parameter adjustments. In all patients with favorable outcome, the initial benefit waned within 4 to 6 wk of continuous stimulation. Therefore, all patients were stimulated on a cyclic schedule, with night arrests.
Objective Measures
Statistical analyses revealed a significant effect of both medication (F[1,7] = 8.12, P < .02) and surgery (F[2,14] = 4.28, P < .03) on the composite gait score with cMRF ON stimulation. Further analyses showed that OFF medication, the composite gait score differed between presurgery vs 12-mo postsurgery (P < .0.3) and vs 24-mo postsurgery (P < .01), with no difference between the 12-and 24-mo assessments. ON medication, the difference was significant at the 24-mo follow-up only (presurgery vs 24-mo postsurgery, P < .02).
Regarding postural stability, analyses revealed a significant effect of medication (F [1, 7] = 10.72, P < .01). The interaction between medication and surgery approached significance (F[2, 14] = 3.54, P = .057). Further examination of this Contacts n • 0 to 3 and contacts 4 to 7 refer respectively to the contacts of the electrodes of the right and left hemisphere. Xbn, Ybn, and Zbn correspond to the coordinates in the BNCS. Xb, Yb, and Zb correspond to coordinates in the BNCS expressed in mm. Mean and SD are indicated. Electrode contacts are the negative active contact used chronically.
trend showed that medication improved postural stability before surgery (P < .03) but no longer after surgery. In addition, the postural stability subscore was improved at the 24-mo follow-up (P < .01) OFF medication only. For the objective evaluation of FOG, we computed the percent of FOG relative to the total duration of the test. 7 Overall, FOG duration decreased by about 58% when patients were tested OFF medication at 1 yr, an effect that was sustained at 2 yr with a mean reduction of 57%. This reduction was significant at the 2 followup assessments (P = .02). ON medication, the overall decrease in FOG during assessment was 51% at 1 yr and 41% at 2 yr. However, there was a great variability between patients and the improvement was not significant. OFF medication, the reduction ranged from 37% to 95% in patients 1, 3, 4, 5, 6, 7, and 10, while it increased by 10% and 25% in patients 2 and 11. Similarly, ON medication the reduction ranged from 45% to 95% in patients 1, 3, 4, 5, 7, and 10, while it increased by 22% in patients 2 and 11. At the individual level, the benefit of cMRF DBS for FOG was not predicted by FOG responsiveness to levodopa prior to surgery.
Subjective Measures
Analyses revealed a significant improvement of the mobility subscore of the PDQ-39 both at 1-and 2-yr follow-up compared to the preoperative state (F[2, 12] = 10.62, P < .01). The PDQ mobility subscore improved from 76 ± 19.7 presurgery to 55 ± 21.5 at 1-yr follow-up, and 41.4 ± 25.4 at 2-yr follow-up. In their diaries, patients 1, 3, 4, 7, 10, and 11 consistently reported a significant reduction of FOG episodes (up to total disappearance in patients 7 and 10), as well as a dramatic reduction of falls related to FOG. Patient 5 reported a moderate decrease in FOG episode, whereas patient 6 reported a highly fluctuating benefit that had waned out 1 yr after surgery. Patient 2 experienced a worsening of her condition.
Case Grouping
According to the clinical evaluations at 24-mo follow-up, patients were classified as "bad responders" (patients 2 and 6), "mild responders" (patient 5), and "good responders" (patients 1, 3, 4, 7, 10, and 11). Among the "good responders," 2 patients (7 and 10) were considered "very good responders" because of total alleviation from FOG.
Patient 6 was considered a "bad responder," because of the lack of actual clinical benefit seen in his diary and frequent clinical evaluations performed during the follow-up period although the occurrence of FOG during the objective gait test was greatly reduced after surgery. cMRF stimulation was switched off after 2 yr as no parameters' setting could provide sustained improvement of FOG.
The data collected from the 2 patients who dropped out of the trial were analyzed and clustered in a group labeled as "No evaluation." Table 4 provides the coordinates of all active contacts of the good responders in the standard and BNCS systems. Table, Supplemental Digital Content 2 provides the coordinates of all the electrode contacts in the Talairach and BNCS. Figure 3 provides the positions of DBS electrodes implanted in the 11 patients on postoperative MRI. Three-dimensional representations of the 11 patients' active contacts are shown in Figures  4A-4E . The normalized localization of "very good responders" active contacts is provided in Figure 4F and showed that they were located slightly more posterior than any other "good responders" active contacts and located around the PMJ.
Anatomoclinical Correlations and Optimal Target in the cMRF
Comparisons of normalized coordinates of "good" vs "bad" responders revealed significant differences in the anteroposterior normalized coordinates Ybn (P < .01, Mann-Whitney U-test; Figure 5 ).
Based on the coordinate's mean value of all the good and very good responders (Table 5 ) the optimal target within the cMRF can be proposed as follows:
• Laterality: Xbn = 2/3 O bn X bn • Anteriority: Ybn = 2/5 O bn Y bn • Depth: Zbn = Ponto-mesencephalic junction Figure 6 illustrates the optimal localization on transverse and sagittal planes. The target can also be seen on the Figure 4F as a blue sphere. In Figure 7 , we provide the localization of the human cholinergic PPN neurons on postmortem tissue in 2 sagittal slices of the brainstem as anatomic information. Note that most of cholinergic neurons are located in the caudal midbrain with few cholinergic neurons found below the PMJ.
FIGURE 5. Coordinates distributions of the "good responders" (white boxes) vs "bad responders" (grey boxes). Coordinates are expressed in the brainstem normalized units. The cross in the "good responders" boxes represents the mean values of the normalized coordinates of the 6 "good responders" represented as a cyan sphere in 3-D figures. Each box extends from the 25th percentile to the 75th percentile; the middle line represents the median; the whiskers demon-
Stimulation of STN and cMRF vs Stimulation of cMRF Alone
Clinical outcomes of the 7 patients implanted in both STN and cMRF showed that 4 were "good responders," 1 was a "mild responder," and 2 were "bad responders." Concerning the 4 patients implanted in the cMRF alone, 2 were good responders, and 2 patients could not be evaluated.
DISCUSSION
Clinical Evaluation
At the group level, evaluation at 1 yr showed a significant improvement of gait and FOG. This effect was sustained at 2 yr. Although it was mainly seen OFF medication, the benefit of cMRF DBS was confirmed by a durable improvement in the PDQ-39 mobility subscore as well as the patients' reports.
The effect on postural stability was marginal. While in some patients FOG greatly improved at 2 yr of follow-up, others patients did not benefit from the procedure. Overall, the results of the objective FOG measurements during the gait test, the composite gait score and the daily recordings of the patients were consistent. Patient 6 did not benefit at the clinical level from cMRF-DBS despite a great improvement of objective measures of FOG. In contrast, patient 11, a good responder, experienced more FOG episodes during objective testing, but his diary recordings, routine clinical evaluation, and improvement of the mobility subscale of the PDQ-39 clearly showed that FOG was significantly reduced under cMRF stimulation. Because improvement of symptoms under conditions of daily living is the ultimate goal of medical care, we classified this patient as good responder. These contradictory effects likely reflect the highly unpredictable nature of FOG, as well as its susceptibility to context and setting. 21 The clustering of the patients in good vs bad responders made sense when examining the location of the active contacts.
Brainstem Normalized Coordinate System
The "Talairach coordinate system" is not ideally suited for the brainstem. Proton density MRI sequences to localize the PPN based on its position in atlases 22, 23 were proposed for direct targeting 24 and further used in different studies. 13, 25, 26 However, coordinates calculation based on pontine and cerebellar landmarks is debatable. We previously expressed contact coordinates in a coordinate system based upon the PMJ. 7 This approach was further used by others. 11, 25, 27 However, coordinate normalization and specific lateral coordinates computation were impossible. The BNCS is based on PMJ, the floor of the fourth ventricle and the lateral mesencephalic sulci which are well delineated on MRI and provide an indirect definition of the target, which can complement the direct PPN targeting.
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Anatomoclinical Correlation
We found that the electrode active contacts in good responders were located in the posterior and central part of the cMRF at the level of the PMJ, that contains the PPN (posterior pars dissipata and pars compacta) and the CfN. However, we would like to stress the caution that should be observed in extrapolating postoperative MRI data of parkinsonian patient (known to have degeneration of some brainstem structures including PPN) to anatomic data provided in brainstem atlas obtained on normal subject following immunohistological procedures. Nevertheless, we provided an immunohistological localization of the cholinergic neurons in sagittal sections of a human brainstem. This allows localizing the human PPN in the caudal midbrain and at the PMJ level where the majority of PPN neurons lie. The PPN located in the cMRF forms, with the laterodorsal tegmental nucleus (in the rostral pons), a column of cholinergic neurons also known as CH5-CH6 complex. 29 In the Paxinos and Huang atlas, 22 the active contacts of the "good responders" were located at the PMJ level (Plate Obex + 31 mm and Obex + 32 mm), corresponding to the PPN pars dissipata. In patients 4 and 7, the active contacts were located just below the PMJ in a more medial position in the pontine-cMRF closed to the superior cerebellar peduncle and the nucleus pontis oralis (Nucleus reticularis pontis rostralis) and the ventrolateral tegmental area. This beneficial site of stimulation, which lies caudal the PPN, was also recently reported 11, 30 and will require further examination.
Where to Stimulate Within the cMRF?
Using the BNCS, we proposed an optimal target associated with normalized coordinates (see Figure 6 ). We propose to have the penultimate contact (n • 1 and n • 5) on the target at the PMJ. This allows to have the lowest contact (n • 0 and n • 4) 2 mm below the PMJ and if necessary, to stimulate rostral pontine areas.
The mechanism of action of cMRF-DBS is still hypothetical. Whether the beneficial effect on FoG is obtained by stimulation of the remaining PPN cholinergic neurons and other noncholinergic neurons of the cMRF (including CfN neurons) or simultaneous stimulation of surrounding fiber system remains an open question. Also, the integrative role of the cMRF in the control of locomotion and attention 31, 32 must be considered and could explain the need for regular parameter adjustments to maintain beneficial effect.
A review of the studies reporting PPN DBS implantations highlighted a large heterogeneity in the electrode positioning within the cMRF.
14 Some studies including our own preliminary report, showed electrode implantation within the caudal midbrain, 7, 13, 26 while others advocated an electrode implantation in the pons below the PMJ, 11, 25, 27, 33, 34 with beneficial clinical outcomes. 35 Unlike a study demonstrated no relation between the position of the electrode and clinical outcomes, 36 the present study provides convincing evidences that the position of the electrode could explain, to some extent, the variability of clinical response. This will have to be confirmed on a larger cohort of patients implanted in the cMRF. In this regard, the use of the BNCS could allow comparing sites of implantation gathered elsewhere, to improve the localization of the optimal target(s).
Limitations
Unlike our initial study at 6 mo based on a double-blind protocol, the present study at 2-yr follow-up is an open-label trial, thus requiring caution when interpreting the clinical outcomes similar to every open-label clinical study. We would like to stress the difficulty to conduct a double-blind study with Parkinson disease patients in advanced stages of the disease. Another limit of the present study is the small number of patients included in the protocol (11 patients) and only 9 patients in the anatomoclinical evaluation due to the impossibility to evaluate 2 patients at long-term evaluation. As an exploratory study based on a small number of patients, it will have to be confirmed in a larger cohort of patients. We think that the use of the BNCS will allow to include more patients in the analysis and, finally, to refine the target position.
CONCLUSION
Variability in clinical response of PPN-DBS remains an open question. Using a new stereotactic procedure adapted to the brainstem, the present anatomoclinical study, while based on a small number of patients, provides arguments for a safe electrode implantation in the posterior cMRF at the level of the PMJ to treat FoG. Whether different sites for electrode implantation in the rostral brainstem provide similar benefit outcomes, opens exciting perspectives in our understanding of this promising but demanding therapeutic approach.
Disclosures
This work was supported by The Michael J. Fox Foundation, the Fondation de France, and the Centre Hospitalier Universitaire de Grenoble Alpes. Medtronic provided the pulse generators free of charge. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr Chabardès serves as consultant for Boston Scientific and for Medtronic and has received financial support from Medtronic for preclinical research purposes in the field of DBS. like this one, ie, characterized by a correct approach and by a rich exposition of data, rather that reviews that in most cases have been merely speculative without offering any substantial contribution to improving DBS in brainstem structures and to understand its mechanism of action. Undoubtedly, the introduction of PPTg DBS has provided new insight for understanding DBS.
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